Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Paul Williams

Sports Medicine Lafayette, LA Medical Doctor

NPI 1861886491 CMS profile 11259800

4212 W Congress St Ste 3100, Lafayette, LA 70506

Open in the dashboard

General payments

$17,350

81 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Williams of Lafayette, LA is reported in the CMS Open Payments database as having received $17,350 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $161 4
2024 General $43 2
2023 General $1,816 22
2022 General $4,093 20
2021 General $11,236 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Williams
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Paul Williams were reported at $161. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Paul Williams Sports Medicine median Middle half National median
2019 $0 $1,176 $199–$4,249 $163
2020 $0 $708 $96–$2,890 $114
2021 $11,236 $1,213 $152–$3,994 $132
2022 $4,093 $1,230 $159–$3,998 $149
2023 $1,816 $584 $146–$2,836 $160
2024 $43 $628 $163–$3,168 $164
2025 $161 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Smith+Nephew, Inc. $6,019 11 payments
  2. Arthrex, Inc. $5,752 43 payments
  3. Alon Medical Technology $4,046 15 payments
  4. Legacy Ortho LLC $1,200 1 payment
  5. Stryker Corporation $275 8 payments
  6. Vericel Corporation $41 2 payments
  7. Ferring Pharmaceuticals Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Education $12,371 9 payments
  2. Travel and Lodging $2,817 10 payments
  3. Food and Beverage $2,162 62 payments
Products named General payments · program years 2021–2025
  1. NOVOSTITCH PRO $890 9 payments
  2. FAST-FIX FLEX $890 9 payments
  3. FAST-FIX 360 $754 6 payments
  4. REGENETEN Shoulder $264 4 payments
  5. Meniscal Root Repair System $136 3 payments
  6. HEALICOIL PK Hip $136 3 payments
  7. BIOSURE $128 1 payment
  8. Q-Fix Mini $128 1 payment
  9. Q-FIX Shoulder $128 1 payment
  10. MAKO $97 2 payments
  11. Other $293 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

196

Median for Orthopedic Surgery: 203

Drug cost

$785

Median for Orthopedic Surgery: $1,433

Branded share of claims

18.4%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 22 $289
Meloxicam Generic 110 $167
Methocarbamol Generic 16 $152
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $104
Ondansetron Odt Ondansetron Brand 13 $55
Tramadol Hcl Generic 12 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$93,242

Of which drugs: $7,350

Medicare patients

278

Average age 73

Services billed

6,958

173 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Diabetes 39%
Ischemic heart disease 37%
Depression 32%
Osteoporosis 23%
Chronic kidney disease 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 11 864 $6,033
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 48 99 $563
Injection, methylprednisolone acetate, 1 mg J1010 Office 44 4,960 $527
Injection, methylprednisolone acetate, 80 mg J1040 Office 22 31 $223

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record